Citation
Alexander, Steve P H., et al. "A Rational Roadmap for SARS-CoV-2/COVID-19 Pharmacotherapeutic Research and Development: IUPHAR Review 29." British Journal of Pharmacology, vol. 177, no. 21, 2020, pp. 4942-4966.
Alexander SPH, Armstrong JF, Davenport AP, et al. A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29. Br J Pharmacol. 2020;177(21):4942-4966.
Alexander, S. P. H., Armstrong, J. F., Davenport, A. P., Davies, J. A., Faccenda, E., Harding, S. D., Levi-Schaffer, F., Maguire, J. J., Pawson, A. J., Southan, C., & Spedding, M. (2020). A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29. British Journal of Pharmacology, 177(21), 4942-4966. https://doi.org/10.1111/bph.15094
Alexander SPH, et al. A Rational Roadmap for SARS-CoV-2/COVID-19 Pharmacotherapeutic Research and Development: IUPHAR Review 29. Br J Pharmacol. 2020;177(21):4942-4966. PubMed PMID: 32358833.
TY - JOUR
T1 - A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29.
AU - Alexander,Steve P H,
AU - Armstrong,Jane F,
AU - Davenport,Anthony P,
AU - Davies,Jamie A,
AU - Faccenda,Elena,
AU - Harding,Simon D,
AU - Levi-Schaffer,Francesca,
AU - Maguire,Janet J,
AU - Pawson,Adam J,
AU - Southan,Christopher,
AU - Spedding,Michael,
Y1 - 2020/07/19/
PY - 2020/04/11/received
PY - 2020/04/27/revised
PY - 2020/04/28/accepted
PY - 2020/5/3/pubmed
PY - 2020/10/28/medline
PY - 2020/5/3/entrez
SP - 4942
EP - 4966
JF - British journal of pharmacology
JO - Br J Pharmacol
VL - 177
IS - 21
N2 - In this review, we identify opportunities for drug discovery in the treatment of COVID-19 and, in so doing, provide a rational roadmap whereby pharmacology and pharmacologists can mitigate against the global pandemic. We assess the scope for targeting key host and viral targets in the mid-term, by first screening these targets against drugs already licensed, an agenda for drug repurposing, which should allow rapid translation to clinical trials. A simultaneous, multi-pronged approach using conventional drug discovery methods aimed at discovering novel chemical and biological means of targeting a short list of host and viral entities which should extend the arsenal of anti-SARS-CoV-2 agents. This longer term strategy would provide a deeper pool of drug choices for future-proofing against acquired drug resistance. Second, there will be further viral threats, which will inevitably evade existing vaccines. This will require a coherent therapeutic strategy which pharmacology and pharmacologists are best placed to provide. LINKED ARTICLES: This article is part of a themed issue on The Pharmacology of COVID-19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc.
SN - 1476-5381
UR - https://www.unboundmedicine.com/medline/citation/32358833/A_rational_roadmap_for_SARS_CoV_2/COVID_19_pharmacotherapeutic_research_and_development:_IUPHAR_Review_29_
DB - PRIME
DP - Unbound Medicine
ER -